celecoxib + esomeprazole + methotrexate

This is a combination of three pharmaceutical agents: - **Celecoxib** is a selective COX-2 inhibitor nonsteroidal anti-inflammatory drug (NSAID) used for pain and inflammation, particularly in arthritis. - **Esomeprazole** is a proton pump inhibitor (PPI) that reduces gastric acid secretion, commonly used to prevent gastrointestinal side effects from NSAIDs or other drugs. - **Methotrexate** is an antimetabolite and antifolate agent with immunosuppressive and antineoplastic properties, widely used in the treatment of rheumatoid arthritis, psoriasis, and various cancers. The combination may be considered for patients requiring methotrexate therapy who are at risk for NSAID-induced gastrointestinal toxicity (hence the inclusion of esomeprazole), or who require additional anti-inflammatory control. However, significant drug-drug interactions exist among these agents. Concomitant use of celecoxib with methotrexate can increase the risk of methotrexate toxicity due to reduced renal clearance[5][6][8]. Esomeprazole may also increase serum levels of methotrexate by reducing its renal elimination[8]. All three are small molecule drugs. Mechanistically: - Celecoxib inhibits prostaglandin synthesis via selective inhibition of cyclooxygenase-2 (COX-2). - Esomeprazole irreversibly inhibits the H+/K+ ATPase in gastric parietal cells. - Methotrexate inhibits dihydrofolate reductase as well as other enzymes involved in nucleotide synthesis; it also modulates adenosine pathways contributing to its anti-inflammatory effect[3][4].